It was a pleasure to meet with Prof. Peter Pappas (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss the interim analysis from the Phase 3 FURI study, investigating oral ibrexafungerp in the treatment of patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals.
The abstract entitled: ‘Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- What is the rationale for the use of ibrexafungerp in patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals? (0:34)
- What are the aims, and design of the FURI Phase III study? (2:05)
- What were the findings of this analysis? (3:40)
- What questions remain unanswered about the use of ibrexafungerp in this indication and what future studies are planned? (5:23)
Disclosures: Peter Pappas receives research support from Cidara, Mayne, Astellas, Gilead and Scynexis; and is also a Scientific advisor for Scynexis, Matinas and F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
